Dark

CAPR
Capricor Therapeutics Inc
stock NASDAQ

Market Open

Jul 27, 2026 11:59:07 AM EDT

6.44USD-67.310%(-13.26)14,910,860

6.43Bid 6.46Ask 0.03Spread

Pre-market

Jul 27, 2026 9:29:30 AM EDT

5.85USD-70.306%(-13.85)1,997,854

After-hours

Jul 24, 2026 4:39:30 PM EDT

19.80USD+0.610%(+0.12)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

09:30AM EST HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $18 Benzinga

Jan 25, 2022

02:58PM EST for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US PR Newswire

07:46AM EST The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data Benzinga

05:04AM EST Capricor Therapeutics, Nippon Shinyaku Announced Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S. Benzinga

05:00AM EST -Partnership Leverages Nippon Shinyakus Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.- GlobeNewswire Inc

Dec 13, 2021

09:19AM EST Capricor Therapeutics Announces Updates On Its Vaccine And Therapeutic Programs For COVID-19 Benzinga

09:15AM EST Capricors Exosome-based mRNA Vaccine for SARS-CoV-2-In-Vivo Preclinical Data Published in the Journal of Biological Chemistry--Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N Protein which may Confer Longer Lasting Immunity--Completing Non-Clinical Studies for IND Submission- GlobeNewswire Inc

Nov 12, 2021

09:15AM EST Capricors CEO Dr. Linda Marbn to GlobeNewswire Inc

Nov 9, 2021

06:14PM EST Capricor Therapeutics Q3 EPS $(0.17) Beats $(0.22) Estimate Benzinga

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 2, 2021

04:05PM EDT Capricor Therapeutics to Present Third Quarter 2021 Financial GlobeNewswire Inc

Oct 11, 2021

07:35AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:19AM EDT HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $14 Benzinga

Sep 27, 2021

06:43AM EDT The following are some of the stocks making big moves in Monday's pre-market trading (as of 6.15 A.M. EDT). RTTNews

Sep 24, 2021

07:01AM EDT Capricor Therapeutics Reports Final Data From Phase 2 HOPE-2 Trial In Patients With Duchenne Muscular Dystrophy Treated With CAP-1002: Trial Met Primary Efficacy Endpoint Benzinga

07:00AM EDT Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01) GlobeNewswire Inc

Sep 22, 2021

04:22PM EDT Capricor Therapeutics To Present At 2 Upcoming Events: Cantor's Global Healthcare Conference Sept. 30, 2021, Call & Gene Meeting On Mesa Oct. 13, 2021 Benzinga

04:05PM EDT -Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 - GlobeNewswire Inc

Sep 19, 2021

09:46AM EDT The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight Benzinga

Sep 7, 2021

09:00AM EDT Capricor Therapeutics to Present at the H.C. Wainwright 23rd GlobeNewswire Inc

Sep 2, 2021

08:36AM EDT Capricor Therapeutics To Present Final Data From HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At World Muscle Society 2021 Benzinga

08:30AM EDT Capricor Therapeutics to Present Final Data from HOPE-2 Trial with GlobeNewswire Inc

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

04:07PM EDT Capricor Therapeutics Q2 EPS $(0.21) Beats $(0.23) Estimate, Sales $204.00K Miss $210.00K Estimate Benzinga

04:01PM EDT CAP-1002 Capricors Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, HOPE-2 Final Data Submitted for Publication- GlobeNewswire Inc

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

08:55AM EDT Capricor Announces Joint Publication With The US Army Institute Of Surgical Research For Cardiosphere-Derived Exosomes As A Potential Therapeutic For Shock Benzinga

08:00AM EDT -Preclinical Data Demonstrates Capricors Exosome Product as an Antishock Therapeutic if Delivered Early GlobeNewswire Inc

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 21, 2021

08:38AM EDT Capricor Therapeutics Filing Shows Registration For $75M Common Stock Shelf Offering Benzinga

Jun 17, 2021

09:02AM EDT Capricor Therapeutics Says To Present Findings From HOPE-2 Open-Label Extension Study At Parent Project Muscular Dystrophy 2021 Conference Benzinga

09:00AM EDT Capricor Therapeutics to Present Findings from HOPE-2 Open-Label GlobeNewswire Inc

Jun 10, 2021

09:15AM EDT Capricor Therapeutics(NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners atBIO Digital 2021being heldJune 10-11andJune 14-18, 2021. GlobeNewswire Inc

May 18, 2021

08:33AM EDT Capricor To Present Preclinical Data For Exosome-mRNA Vaccine for SARS-CoV-2 International Society For Extracellular Vesicles Annual Meeting Benzinga

08:30AM EDT -Capricors Findings Support Expansion Across Multiple Therapeutic Targets- GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 13, 2021

04:20PM EDT Capricor Therapeutics Q1 EPS $(0.23) Up From $(0.30) YoY, Sales $40.82K Down From $185.69K YoY Benzinga

04:05PM EDT --Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- GlobeNewswire Inc

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

May 12, 2021

09:00AM EDT --Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery-- GlobeNewswire Inc

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 6, 2021

08:30AM EDT Capricor Therapeutics to Present First Quarter 2021 Financial GlobeNewswire Inc

Apr 29, 2021

11:51AM EDT Capricor Therapeutics Stock Jumps On Engineered Exosomes Development Pact Benzinga

10:24AM EDT Mid-Morning Market Update: Markets Open Higher; McDonald's Profit Beats Estimates Benzinga

08:06AM EDT Capricor Therapeutics Signs Exclusive Worldwide License Agreement With Johns Hopkins University To Include Engineered Exosomes For Vaccines And Therapeutics As Part Of The Company's Exosome Technology Portfolio; Financial Details Not Disclosed Benzinga

08:00AM EDT Capricor Therapeutics Signs Exclusive Worldwide License Agreement GlobeNewswire Inc

Mar 12, 2021

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

04:01PM EST Capricor Therapeutics Q4 EPS $(0.21) Up From $(0.34) YoY, Sales $57.83K Miss $210.00K Estimate Benzinga

04:01PM EST Exosomes Platform Technology-Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes- GlobeNewswire Inc

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

03:35AM EST Earnings Scheduled For March 11, 2021 Benzinga

Mar 9, 2021

09:19AM EST Capricor Therapeutics Highlights New Advances From Preclinical Study For Multivalent Exosome-Based mRNA Vaccine For COVID-19 Has Been Posted On bioRxiv Preprint Server Benzinga

09:15AM EST -New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- GlobeNewswire Inc

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 4, 2021

09:00AM EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 1, 2021

09:20AM EST Capricor Therapeutics Announces Development Of Serology Test To Confirm Activity Of SARS-CoV-2 Vaccines Benzinga

09:15AM EST Capricor Therapeutics Announces Development of Serology Test to GlobeNewswire Inc

Jan 19, 2021

09:17AM EST Capricor Therapeutics Reports Publication Of Demonstrating Methods For Enhanced Potency Of Cardiosphere-Derived Exosomes Benzinga

09:15AM EST -Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- GlobeNewswire Inc

Jan 12, 2021

09:12AM EST Capricor Collaborates With Lonza For The Development Of CAP-1002, Its Cell Therapy Candidate For The Treatment Of Duchenne Muscular Dystrophy And Other Indications Benzinga

09:05AM EST Capricor to leverage Lonzas expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply GlobeNewswire Inc

Dec 29, 2020

09:16AM EST Capricor Therapeutics Announces DSMB Recommendation To Continue Phase II INSPIRE Trial For Severe COVID-19 Patients Benzinga

09:15AM EST Capricor Therapeutics Announces DSMB Recommendation to Continue GlobeNewswire Inc

Nov 24, 2020

07:30AM EST Capricor Therapeutics Commences Dosing Patients In Phase 2 Trial Of CAP-1002 In Patients With Severe COVID-19 Benzinga

07:30AM EST Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial GlobeNewswire Inc

Nov 12, 2020

04:05PM EST Capricor Therapeutics Q3 EPS $(0.20) Beats $(0.37) Estimate, Sales $16.86K Miss $210.00K Estimate Benzinga

04:01PM EST Exosome Platform Technology-Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19--Novel Vaccine Induced Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins--Development of Safe, Non-toxic Exosome Formulation Capable of Delivering Functional mRNA in vitro and in vivo--Platform Expansion Underway Using Engineered Exosomes- GlobeNewswire Inc

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 9, 2020

09:20AM EST Capricor Therapeutics Q3 EPS $(0.20) Up From $(0.43) YoY Benzinga

09:19AM EST Capricor Therapeutics Announces Positive Preclinical Data For Multivalent Exosome-mRNA Vaccine For COVID-19 Benzinga

09:15AM EST Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins GlobeNewswire Inc

Sep 23, 2020

10:25AM EDT Shares of Capricor Therapeutics, Inc. (CAPR) are rising over 6% on Wednesday morning on news that it will announce final results from a mid stage trial of its duchenne muscular dystrophy treatment on October 1. RTTNews

09:38AM EDT Capricor To Present Novel Data From Phase II HOPE-2 Clinical Trial RTTNews

09:27AM EDT Capricor Therapeutics Reports Will Present Results From HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At International World Muscle Society Virtual Congress 2020 Oct. 1 At 12:30 p.m. EDT Benzinga

09:25AM EDT --Final 12-Month Results from Phase II Trial to be Presented on October 1-- GlobeNewswire Inc

Sep 10, 2020

09:15AM EDT Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual GlobeNewswire Inc

Aug 25, 2020

04:36PM EDT Capricor Therapeutics Inc Unit, Cedars-Sinai Medical Center Entered Into Amendment To Exclusive License Agreement Benzinga

11:34AM EDT Why Capricor Therapeutics Is Trading Higher Today Benzinga

09:17AM EDT Capricor Therapeutics Announces FDA Acceptance Of Its IND Application For A Phase 2 Clinical Trial Of CAP-1002 In Patients With COVID-19 Benzinga

09:15AM EDT The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 GlobeNewswire Inc

Aug 6, 2020

04:19PM EDT Capricor Therapeutics Q2 EPS $(0.23) Beats $(0.34) Estimate, Sales $49.86K May Not Compare To $210.00K Estimate Benzinga

Aug 4, 2020

10:37AM EDT Capricor Therapeutics Shares Spike Higher After Study Co. Sponsored Was Published Titled 'European Heart Journal: Cell Infusions Benefit Heart Patients' Benzinga

Jul 30, 2020

09:15AM EDT Capricor Therapeutics to Present Second Quarter 2020 Financial GlobeNewswire Inc

Jul 20, 2020

05:11AM EDT 80 Biggest Movers From Friday Benzinga